

# *Emerging-Trends:* Executive Laser Report OPHTHALMIC AND MEDICAL LASER HIGHLIGHTS December 2012

Volume VII No. 12

laser@emerging-trends.com

January 15, 2013

Here are the December highlights, which give you a taste of how much news there was last month. Please consider subscribing to *Executive Laser Report* and to our sister publication, *Trends-in-Medicine*.

## OPHTHALMIC LASER HIGHLIGHTS

### Financial News

- **Abbott**'s board of directors approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie, and declared a special dividend distribution of all of the outstanding shares of AbbVie common stock. The board also declared its 356<sup>th</sup> consecutive quarterly cash dividend – \$0.14 per share, payable February 15, 2013. AbbVie intends to recommend a cash dividend, subject to AbbVie's board approval, of \$0.40 per share, which together with Abbott's dividend will equal a cash dividend of \$0.54 per share, an increase of nearly 6% over Abbott's quarterly cash dividend declared in September 2012.
- There are reports that **Bausch + Lomb** has hired Goldman Sachs to explore a sale of the company, hoping to fetch more than \$10 billion. Reportedly, if it doesn't sell the company, owner Warburg Pincus will pursue an IPO.
- **Carl Zeiss Meditec** said that it continued its growth trend in financial year 2011/2012. Revenue climbed 13.6% to €861.9 million and thus slightly exceeded the upper limit of the revenue forecast. The company had double-digit growth rates in revenue and its operating result, and grew significantly in the past financial year (ended September 30, 2012).
- **Iridex** announced the final results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of \$4.10 per share, which expired on December 7, 2012. The company accepted for payment an aggregate of 487,500 shares of its common stock, including all "odd lots" properly tendered, at a purchase price of \$4.10 per share, for a total cost of ~\$2 million.

### Other News

- The Center for Eye Research Australia (CERA) has started to recruit patients for a multicenter trial looking at the clinical efficacy of retinal rejuvenation therapy, or **Ellex 2RT**, in the treatment of early wet age-related macular degeneration (AMD).
- **Iridex** received FDA 510(k) clearance and a CE Mark for the TxCell scanning laser delivery system.
- **LensAR**'s laser system received FDA 510(k) clearance for executing corneal incisions during cataract surgery.

---

2731 N.E. Pinecrest Lakes Blvd.  
Jensen Beach, FL 34957  
772-334-7409 • Fax 772-334-0856  
www.emerging-trends.com

**Publisher:** Stephen Snyder  
**Managing Editor:** Michael Woods  
**Contributing Editor:** D. Woods  
**Editor:** Betty Teel

*The information and opinions expressed in Executive Laser Report have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright © 2013. This document may not be reproduced without written permission of the publisher.*

**MEDICAL/SURGICAL LASER HIGHLIGHTS****Financial News**

- **Coherent** bought the German company Lumera Laser for approximately \$52 million in cash.
- **PhotoMedex** said that it expects 4Q12 revenue to increase by more than 80% year-to-year and to be between \$52 million and \$54 million.
- **Synergetics USA** had growth in sales, gross profit, operating margin, income from continuing operations, and net income for the first quarter ended October 31, 2012.
- The law firm of Burke, Harvey & Frankowski is investigating **Vascular Solutions** to determine whether the company's officers were involved in marketing some of its medical devices for off-label use.

**Other News**

- **Alma Lasers** and its UK partner, ABC Lasers, were awarded three medals at the Aesthetic Awards show.
- **Cynosure** received FDA 510(k) clearance for its PicoSure laser workstation for the removal of tattoos and benign pigmented lesions.
- **Lutronic** received FDA 510(k) clearance for its Healite II, an 830 nm LED phototherapy system.
- An FDA warning letter was sent to **MedArt's** UK headquarters on November 19, 2012. The letter complained of non-compliant conditions at the company's manufacturing facility in Hvidovre, Denmark, found during a May 29, 2012, inspection.
- **Solta Medical** and SkinCeuticals have a partnership to deliver the first fractional laser treatment plus in-office and home use antioxidant skincare regimen in Canada.

